Cargando…

Feasibility of Non-TBI Conditioning with Busulfan and Fludarabine for Allogeneic Stem Cell Transplantation in Lymphoid Malignancy

BACKGROUND/AIMS: This retrospective study evaluated the transplantation outcomes of patients with adult lymphoid malignancies who received chemotherapy-based conditioning with busulfan and fludarabine (BuFlu) and busulfan and cyclophosphamide (BuCy2). METHODS: Thirty-eight patients (34 with acute ly...

Descripción completa

Detalles Bibliográficos
Autores principales: Shin, Ho Cheol, Lee, Yoo Jin, Joon Ho, Joon Ho, Lee, Soo Jung, Kang, Byung Woog, Chae, Yee Soo, Kim, Jong Gwang, Choi, Jun Young, Seo, Jong Won, Kim, Yu Kyung, Suh, Jang Soo, Sohn, Sang Kyun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Korean Association of Internal Medicine 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3295992/
https://www.ncbi.nlm.nih.gov/pubmed/22403503
http://dx.doi.org/10.3904/kjim.2012.27.1.72
_version_ 1782225658398638080
author Shin, Ho Cheol
Lee, Yoo Jin
Joon Ho, Joon Ho
Lee, Soo Jung
Kang, Byung Woog
Chae, Yee Soo
Kim, Jong Gwang
Choi, Jun Young
Seo, Jong Won
Kim, Yu Kyung
Suh, Jang Soo
Sohn, Sang Kyun
author_facet Shin, Ho Cheol
Lee, Yoo Jin
Joon Ho, Joon Ho
Lee, Soo Jung
Kang, Byung Woog
Chae, Yee Soo
Kim, Jong Gwang
Choi, Jun Young
Seo, Jong Won
Kim, Yu Kyung
Suh, Jang Soo
Sohn, Sang Kyun
author_sort Shin, Ho Cheol
collection PubMed
description BACKGROUND/AIMS: This retrospective study evaluated the transplantation outcomes of patients with adult lymphoid malignancies who received chemotherapy-based conditioning with busulfan and fludarabine (BuFlu) and busulfan and cyclophosphamide (BuCy2). METHODS: Thirty-eight patients (34 with acute lymphoblastic leukemia and 4 with lymphoblastic lymphoma) were included in the current study. The conditioning regimen was BuCy2 for 14 patients and BuFlu for the remaining 24 patients. Eight and 13 patients were high risk disease in the BuCy2 and BuFlu groups, respectively. RESULTS: The cumulative incidence of grade II-IV acute graft-versus-host disease (GVHD) was 56.5% and 55.2% and that of extensive chronic GVHD 17.0% and 55.6% (p = 0.018) for the BuFlu and BuCy2 groups, respectively. The 3-year relapse rate was 27.8% and 31.4% and 3-year overall survival 34.3% and 46.8% for the BuFlu and BuCy2 groups, respectively. Treatment-related mortality (TRM) was significantly lower in the BuFlu group (16.9%) than in the BuCy2 group (57.1%, p = 0.010). In multivariate analyses, the BuFlu regimen was identified as an independent favorable risk factor for TRM (hazard ratio [HR], 0.036; p = 0.017) and extensive chronic GVHD (HR, 0.168; p = 0.034). CONCLUSIONS: Our BuFlu regimen would appear to be an acceptable conditioning option for lymphoid malignancies, including high-risk diseases. It was safely administered with a lower TRM rate than BuCy2 conditioning.
format Online
Article
Text
id pubmed-3295992
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher The Korean Association of Internal Medicine
record_format MEDLINE/PubMed
spelling pubmed-32959922012-03-08 Feasibility of Non-TBI Conditioning with Busulfan and Fludarabine for Allogeneic Stem Cell Transplantation in Lymphoid Malignancy Shin, Ho Cheol Lee, Yoo Jin Joon Ho, Joon Ho Lee, Soo Jung Kang, Byung Woog Chae, Yee Soo Kim, Jong Gwang Choi, Jun Young Seo, Jong Won Kim, Yu Kyung Suh, Jang Soo Sohn, Sang Kyun Korean J Intern Med Original Article BACKGROUND/AIMS: This retrospective study evaluated the transplantation outcomes of patients with adult lymphoid malignancies who received chemotherapy-based conditioning with busulfan and fludarabine (BuFlu) and busulfan and cyclophosphamide (BuCy2). METHODS: Thirty-eight patients (34 with acute lymphoblastic leukemia and 4 with lymphoblastic lymphoma) were included in the current study. The conditioning regimen was BuCy2 for 14 patients and BuFlu for the remaining 24 patients. Eight and 13 patients were high risk disease in the BuCy2 and BuFlu groups, respectively. RESULTS: The cumulative incidence of grade II-IV acute graft-versus-host disease (GVHD) was 56.5% and 55.2% and that of extensive chronic GVHD 17.0% and 55.6% (p = 0.018) for the BuFlu and BuCy2 groups, respectively. The 3-year relapse rate was 27.8% and 31.4% and 3-year overall survival 34.3% and 46.8% for the BuFlu and BuCy2 groups, respectively. Treatment-related mortality (TRM) was significantly lower in the BuFlu group (16.9%) than in the BuCy2 group (57.1%, p = 0.010). In multivariate analyses, the BuFlu regimen was identified as an independent favorable risk factor for TRM (hazard ratio [HR], 0.036; p = 0.017) and extensive chronic GVHD (HR, 0.168; p = 0.034). CONCLUSIONS: Our BuFlu regimen would appear to be an acceptable conditioning option for lymphoid malignancies, including high-risk diseases. It was safely administered with a lower TRM rate than BuCy2 conditioning. The Korean Association of Internal Medicine 2012-03 2012-02-28 /pmc/articles/PMC3295992/ /pubmed/22403503 http://dx.doi.org/10.3904/kjim.2012.27.1.72 Text en Copyright © 2012 The Korean Association of Internal Medicine http://creativecommons.org/licenses/by-nc/3.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Shin, Ho Cheol
Lee, Yoo Jin
Joon Ho, Joon Ho
Lee, Soo Jung
Kang, Byung Woog
Chae, Yee Soo
Kim, Jong Gwang
Choi, Jun Young
Seo, Jong Won
Kim, Yu Kyung
Suh, Jang Soo
Sohn, Sang Kyun
Feasibility of Non-TBI Conditioning with Busulfan and Fludarabine for Allogeneic Stem Cell Transplantation in Lymphoid Malignancy
title Feasibility of Non-TBI Conditioning with Busulfan and Fludarabine for Allogeneic Stem Cell Transplantation in Lymphoid Malignancy
title_full Feasibility of Non-TBI Conditioning with Busulfan and Fludarabine for Allogeneic Stem Cell Transplantation in Lymphoid Malignancy
title_fullStr Feasibility of Non-TBI Conditioning with Busulfan and Fludarabine for Allogeneic Stem Cell Transplantation in Lymphoid Malignancy
title_full_unstemmed Feasibility of Non-TBI Conditioning with Busulfan and Fludarabine for Allogeneic Stem Cell Transplantation in Lymphoid Malignancy
title_short Feasibility of Non-TBI Conditioning with Busulfan and Fludarabine for Allogeneic Stem Cell Transplantation in Lymphoid Malignancy
title_sort feasibility of non-tbi conditioning with busulfan and fludarabine for allogeneic stem cell transplantation in lymphoid malignancy
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3295992/
https://www.ncbi.nlm.nih.gov/pubmed/22403503
http://dx.doi.org/10.3904/kjim.2012.27.1.72
work_keys_str_mv AT shinhocheol feasibilityofnontbiconditioningwithbusulfanandfludarabineforallogeneicstemcelltransplantationinlymphoidmalignancy
AT leeyoojin feasibilityofnontbiconditioningwithbusulfanandfludarabineforallogeneicstemcelltransplantationinlymphoidmalignancy
AT joonhojoonho feasibilityofnontbiconditioningwithbusulfanandfludarabineforallogeneicstemcelltransplantationinlymphoidmalignancy
AT leesoojung feasibilityofnontbiconditioningwithbusulfanandfludarabineforallogeneicstemcelltransplantationinlymphoidmalignancy
AT kangbyungwoog feasibilityofnontbiconditioningwithbusulfanandfludarabineforallogeneicstemcelltransplantationinlymphoidmalignancy
AT chaeyeesoo feasibilityofnontbiconditioningwithbusulfanandfludarabineforallogeneicstemcelltransplantationinlymphoidmalignancy
AT kimjonggwang feasibilityofnontbiconditioningwithbusulfanandfludarabineforallogeneicstemcelltransplantationinlymphoidmalignancy
AT choijunyoung feasibilityofnontbiconditioningwithbusulfanandfludarabineforallogeneicstemcelltransplantationinlymphoidmalignancy
AT seojongwon feasibilityofnontbiconditioningwithbusulfanandfludarabineforallogeneicstemcelltransplantationinlymphoidmalignancy
AT kimyukyung feasibilityofnontbiconditioningwithbusulfanandfludarabineforallogeneicstemcelltransplantationinlymphoidmalignancy
AT suhjangsoo feasibilityofnontbiconditioningwithbusulfanandfludarabineforallogeneicstemcelltransplantationinlymphoidmalignancy
AT sohnsangkyun feasibilityofnontbiconditioningwithbusulfanandfludarabineforallogeneicstemcelltransplantationinlymphoidmalignancy